nach oben

Diabetologia

Erschienen in:

01.06.2010 | Commentary

Is type 2 diabetes an amyloidosis and does it really matter (to patients)?

verfasst von: G. J. S. Cooper, J. F. Aitken, S. Zhang

Erschienen in: Diabetologia | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Excerpt

Degeneration of pancreatic islet beta cells is increasingly ranked as a key disease mechanism in type 2 diabetes [1, 2], but it is not entirely clear what the underlying molecular processes might be and how they attack insulin production, ultimately causing type 2 diabetes [3, 4]. …

Hamming KSC, Soliman D, Matemisz LC et al (2009) Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K⁺ channel. Diabetes 58:2419–2424CrossRefPubMed

Jonsson A, Isomaa B, Tuomi T et al (2009) A variant in the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin secretion. Diabetes 58:2409–2413CrossRefPubMed

Leahy JL (1990) Natural history of β-cell dysfunction in NIDDM. Diabetes Care 13:992–1010CrossRefPubMed

Leahy JL (2005) β-cell dysfunction in type 2 diabetes mellitus. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ (eds) Joslin's diabetes mellitus, 14th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 449–461

Gepts W (1981) Islet changes in human diabetes. In: Cooperstein GJ, Watkins D (eds) The islets of Langerhans. Academic, New York, pp 321–356

Clark A, Wells CA, Buley ID et al (1988) Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas of type 2 diabetic patients. Diabetes Res 9:151–159PubMed

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMed

Deng S, Vatamaniuk M, Huang X et al (2004) Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53:624–632CrossRefPubMed

Poitout V, Robertson RP (2002) Secondary beta-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinol 143:339–342CrossRef

10.

Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8:657–662CrossRefPubMed

11.

Zraika S, Hull RL, Verchere CB et al (2010) Toxic oligomers and islet beta-cell death: guilty by association or convicted by circumstantial evidence? Diabetologia. doi:10.1007/s00125-010-1671-6 PubMed

12.

Opie EL (1900–01) The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med 5:527–540

13.

Bell ET (1952) Hyalinization of the islet of Langerhans in diabetes mellitus. Diabetes 1:341–344PubMed

14.

Zhao HL, Lai FM, Tong PC et al (2003) Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 52:2759–2766CrossRefPubMed

15.

Clark A, Cooper GJS, Lewis CE et al (1987) Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet ii:231–234CrossRef

16.

Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77:91–94PubMed

17.

Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628–8632CrossRefPubMed

18.

Bell ET (1959) Hyalanization of the islets of Langerhans in nondiabetic individuals. Am J Pathol 35:801–805PubMed

19.

Cooper GJS (1994) Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 15:163–201PubMed

20.

Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84:3881–3885CrossRefPubMed

21.

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356CrossRefPubMed

22.

Goldberg MS, Lansbury PT Jr (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson’s disease? Nat Cell Biol 2:E115–E119CrossRefPubMed

23.

Hatters DM (2008) Protein misfolding inside cells: the case of huntingtin and Huntington's disease. IUBMB Life 60:724–728CrossRefPubMed

24.

Thompson AJ, Barrow CJ (2002) Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. Curr Med Chem 9:1751–1762PubMed

25.

Smirnovas V, Kim JI, Lu X, Atarashi R, Caughey B, Surewicz WK (2009) Distinct structures of scrapie prion protein (PrP_SC)-seeded vs spontaneous recombinant prion protein fibrils revealed by hydrogen/deuterium exchange. J Biol Chem 284:24233–24241CrossRefPubMed

26.

Goldsbury CS, Cooper GJS, Goldie KN et al (1997) Polymorphic fibrillar assembly of human amylin. J Struct Biol 119:17–27CrossRefPubMed

27.

Cardoso I, Saraiva MJ (2005) Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 20:234–239CrossRef

28.

Benson MD, Wallace MR (1989) Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease: volume II. McGraw Hill, New York, pp 2439–2460

29.

Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159:1993–2000PubMed

30.

Palsdottir A, Helgason A, Palsson S et al (2008) A drastic reduction in the life span of cystatin C L68Q carriers due to life-style changes during the last two centuries. PLoS Genet 4:e1000099CrossRefPubMed

31.

Atouf F, Czernichow P, Scharfmann R (1997) Expression of neuronal traits in pancreatic β-cells: implication of neuron-restrictive silencing factor/repressor element silencing transcription factor, a neuron-restrictive silencer. J Biol Chem 272:1929–1934CrossRefPubMed

32.

MacGibbon G, Cooper GJS, Dragunow M (1998) Acute application of amylin, unlike β-amyloid peptides, kills undifferentiated PC12 cells by apoptosis. Neuroreport 8:3945–3949CrossRef

33.

Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036–5040CrossRefPubMed

34.

Cooper GJS, Day AJ, Willis AC, Roberts AN, Reid KBM, Leighton B (1989) Amylin and the amylin gene: structure, function, and relationship to islet amyloid and to diabetes mellitus. Biochim Biophys Acta 1014:247–258CrossRefPubMed

35.

Goldsbury C, Goldie K, Pellaud J et al (2000) Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol 130:352–362CrossRefPubMed

36.

Goldsbury C, Kistler J, Aebi U, Arvinte T, Cooper GJS (1999) Watching amyloid fibrils grow by time lapse atomic force microscopy. J Mol Biol 285:33–39CrossRefPubMed

37.

Green JD, Goldsbury C, Kistler J, Cooper GJS, Aebi U (2004) Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. J Biol Chem 279:12206–12212CrossRefPubMed

38.

Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29:303–316CrossRefPubMed

39.

Aitken JF, Loomes KM, Scott DW et al (2010) Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin transgenic mice. Diabetes 59:161–171CrossRefPubMed

40.

Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJS (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. FEBS J 273:3614–3624CrossRefPubMed

41.

Zhang S, Liu J, Dragunow M, Cooper GJS (2003) Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1. J Biol Chem 278:52810–52819CrossRefPubMed

42.

Zhang S, Liu H, Yu H, Cooper GJS (2008) Fas-associated death receptor signaling evoked by human amylin in islet β-cells. Diabetes 57:348–356CrossRefPubMed

43.

Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498CrossRefPubMed

44.

Lin CY, Gurlo T, Kayed R et al (2007) Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 56:1324–1332CrossRefPubMed

45.

Leighton B, Cooper GJS (1988) Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335:632–663CrossRefPubMed

46.

Roberts AN, Leighton B, Todd JA et al (1989) Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci U S A 86:9662–9666CrossRefPubMed

47.

Cooper GJS (2001) Amylin: physiology and pathophysiology. In: Jefferson LS, Cherrington AD (eds) The handbook of physiology, section 7, the endocrine pancreas and regulation of metabolism. American Physiological Society, Oxford University Press, New York, pp 303–396

48.

Zhang S, Liu J, Saafi EL, Cooper GJS (1999) Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett 455:315–320CrossRefPubMed

49.

Saafi E, Konarkowska B, Zhang S, Kistler J, Cooper GJS (2001) Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β-cells. Cell Biol Int 25:339–350CrossRefPubMed

50.

Zhang S, Liu H, Liu J, Tse CA, Dragunow M, Cooper GJS (2006) Activation of activating transcription factor 2 by p38 MAP kinase during apoptosis induced by human amylin in cultured pancreatic β-cells. FEBS J 273:3779–3791CrossRefPubMed

51.

Fox N, Schrementi J, Nishi M et al (1993) Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 323:40–44CrossRefPubMed

52.

Verchere CB, D’Alessio DA, Palmiter RD, Kahn SE (1994) Transgenic mice overproducing islet amyloid polypeptide have increased insulin storage and secretion in vitro. Diabetologia 37:725–728CrossRefPubMed

53.

de Koning EJP, Morris ER, Hofhuis FM et al (1994) Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 91:8467–8471CrossRefPubMed

54.

Janson J, Soeller WC, Roche PC et al (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:7283–7288CrossRefPubMed

55.

Wong WPS, Scott DW, Ferreira A et al (2008) Spontaneous diabetes in hemizygous human amylin transgenic mice that developed neither islet amyloid nor peripheral insulin resistance. Diabetes 57:2737–2744CrossRefPubMed

56.

Aitken JF, Loomes KM, Konarkowska B, Cooper GJS (2003) Suppression of the conversion of human amylin into insoluble amyloid by polycyclic compounds. Biochem J 374:779–784CrossRefPubMed

57.

Treusch S, Cyr DM, Lindquist S (2009) Amyloid deposits: protection against toxic protein species? Cell Cycle 8:1668–1674PubMed

Titel: Is type 2 diabetes an amyloidosis and does it really matter (to patients)?
verfasst von: G. J. S. Cooper
J. F. Aitken
S. Zhang
Publikationsdatum: 01.06.2010
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1715-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)α1-specific activity and glucose transport in human skeletal muscle

Oligodeoxynucleotide IMT504 induces a marked recovery in a streptozotocin-induced model of diabetes in rats: correlation with an early increase in the expression of nestin and neurogenin 3 progenitor cell markers

Erratum to: Assessing the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 finnish adults

Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity

Down’s syndrome in diabetic patients aged <20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes